Get the Stockscreener App
7.60
0.40%
0.03
Pre-market:
7.60
Bioventus Inc stock is traded at $7.60, with a volume of 176.09K.
It is up +0.40% in the last 24 hours and up +0.66% over the past month.
Bioventus Inc is a medical technology company. The company is engaged in developing and commercializing clinically differentiated treatments that engage and enhance the body's natural healing process. It offers a diverse portfolio of products to serve physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Its portfolio of products is grouped into three verticals based on clinical use: Pain Treatments, Surgical Solutions, and Restorative Therapies. Geographical presence is in the United States which derives key revenue, and International markets.
See More
Previous Close:
$7.57
Open:
$7.59
24h Volume:
176.09K
Relative Volume:
0.58
Market Cap:
$509.02M
Revenue:
$555.06M
Net Income/Loss:
$-39.48M
P/E Ratio:
-12.67
EPS:
-0.6
Net Cash Flow:
$29.05M
1W Performance:
-0.65%
1M Performance:
+0.66%
6M Performance:
+16.39%
1Y Performance:
-31.16%
1-Day Range:
$7.47
$7.64
1-Week Range:
$7.33
$7.73
52-Week Range:
$5.81
$11.89
Bioventus Inc Stock (BVS) Company Profile
Name
Bioventus Inc
Sector
Industry
Phone
(919) 474-6700
Address
4721 EMPEROR BOULEVARD, SUITE 100, DURHAM
Compare BVS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BVS
Bioventus Inc
|
7.60 | 507.01M | 555.06M | -39.48M | 29.05M | -0.60 |
|
ABT
Abbott Laboratories
|
125.40 | 217.86B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
97.72 | 146.12B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
364.35 | 139.95B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
101.99 | 130.73B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
85.78 | 48.73B | 5.88B | 1.34B | 799.60M | 2.3489 |
Bioventus Inc Stock (BVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-07-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-17-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-07-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-09-23 | Upgrade | Craig Hallum | Hold → Buy |
| Nov-22-22 | Downgrade | Craig Hallum | Buy → Hold |
| Nov-09-22 | Downgrade | Canaccord Genuity | Buy → Hold |
| Nov-09-22 | Downgrade | JP Morgan | Overweight → Underweight |
| Mar-15-22 | Initiated | Craig Hallum | Buy |
| Nov-15-21 | Resumed | Morgan Stanley | Overweight |
| Nov-10-21 | Resumed | JP Morgan | Overweight |
| Jul-01-21 | Downgrade | Goldman | Buy → Neutral |
| Mar-08-21 | Initiated | Canaccord Genuity | Buy |
| Mar-08-21 | Initiated | Goldman | Buy |
| Mar-08-21 | Initiated | JP Morgan | Overweight |
| Mar-08-21 | Initiated | Morgan Stanley | Overweight |
View All
Bioventus Inc Stock (BVS) Latest News
Will Bioventus Inc. stock reach Wall Street targetsTrade Exit Summary & Real-Time Market Sentiment Reports - Newser
Will Bioventus Inc. stock see insider buyingWeekly Stock Report & Short-Term High Return Ideas - Newser
(BVS) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
Bioventus: A New Start (NASDAQ:BVS) - Seeking Alpha
How Bioventus Inc. stock performs in weak economy2025 Top Gainers & Reliable Volume Spike Alerts - Newser
Bioventus (NYSE:BVS) Trading Down 3.9%Here's What Happened - MarketBeat
Bioventus, Inc. Reports Strong Q3 Earnings Growth - MSN
Segall Bryant & Hamill LLC Purchases 232,302 Shares of Bioventus Inc. $BVS - MarketBeat
Bioventus (NASDAQ:BVS) Seems To Use Debt Quite Sensibly - 富途牛牛
[Form 3] Bioventus Inc. Initial Statement of Beneficial Ownership - Stock Titan
Bioventus to Present at the Piper Sandler 37th Annual Healthcare Conference - The Manila Times
Bioventus (Nasdaq: BVS) to present at Piper Sandler 37th Healthcare Conference webcast - Stock Titan
Bioventus (NYSE:BVS) Shares Up 9.9%Time to Buy? - MarketBeat
Bioventus Appoints Ajay Dhankhar as New Director - MSN
Is Bioventus Inc. stock affected by interest rate hikesRisk Management & Weekly Chart Analysis and Guides - newser.com
Why Bioventus Inc. stock appeals to analystsJuly 2025 Decliners & Weekly Market Pulse Updates - newser.com
Is Bioventus Inc. stock attractive for income investorsMarket Trend Review & Risk Adjusted Buy and Sell Alerts - newser.com
Bioventus Inc. stock prediction for this weekDollar Strength & High Conviction Investment Ideas - newser.com
Smart tools for monitoring Bioventus Inc.’s price actionEarnings Beat & Technical Pattern Alert System - newser.com
Can Bioventus Inc. rally from current levelsJuly 2025 Catalysts & Community Trade Idea Sharing Platform - newser.com
Bioventus Inc. (BVS) Stock Forecast 2026, 2030 & 7-Year Price Prediction | Meyka AI - Meyka
Bioventus appoints Ajay Dhankhar to board as Class II director By Investing.com - Investing.com Australia
Bioventus appoints Ajay Dhankhar to board as Class II director - Investing.com
Bioventus Inc. Appoints Ajay Dhankhar to Board of Directors - TradingView
Bioventus Inc. Appoints Ajay Dhankhar to the Board as Class II Director, Effective November 14, 2025 - MarketScreener
[8-K] Bioventus Inc. Reports Material Event | BVS SEC FilingForm 8-K - Stock Titan
Campbell & CO Investment Adviser LLC Makes New Investment in Bioventus Inc. $BVS - MarketBeat
Backtesting results for Bioventus Inc. trading strategiesJuly 2025 Breakouts & Technical Buy Zone Confirmations - newser.com
Will Bioventus Inc. stock deliver long term returnsMarket Growth Report & Safe Capital Growth Trade Ideas - newser.com
Will Bioventus Inc. stock maintain momentum in 2025Treasury Yields & Technical Analysis for Trade Confirmation - newser.com
Developing predictive dashboards with Bioventus Inc. dataQuarterly Portfolio Report & AI Forecast for Swing Trade Picks - newser.com
How strong is Bioventus Inc. stock revenue growthEarnings Risk Report & High Return Stock Watch Alerts - newser.com
Why Bioventus Inc. stock is trending among retail traders2025 Retail Activity & Real-Time Stock Entry Alerts - newser.com
Bioventus Inc Stock (BVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.89%
4.92%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):